Skip to content

High-Dose Influenza Vaccine in Nursing Homes

High Dose Influenza Vaccination and Morbidity & Mortality in U.S. Nursing Homes

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01815268
Enrollment
823
Registered
2013-03-21
Start date
2013-02-28
Completion date
2018-09-30
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Randomized Controlled Trial, Influenza, Influenza vaccine, Flu Vaccine, Fluzone, HD Fluzone, Nursing Home, Hospitalization, Mortality, Health Care worker vaccination, ADL decline, Effectiveness, Elderly, Morbidity, Nursing Home resident, Frail, Institutionalized, Epidemiology, CDC, US, city

Brief summary

The purpose of this study is to prospectively evaluate relative effectiveness of high dose influenza vaccine in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the standard dose trivalent seasonal influenza vaccine.

Detailed description

SUMMARY: This nationally representative study samples from estimated 6782 Medicare-certified nursing homes co-located within 50 miles of the 122 cities reporting to Center for Disease Control and Prevention (CDC) weekly influenza surveillance. In total, 1000 facilities will be enrolled for random assignment to either: 1) the licensed high dose (HD) trivalent influenza vaccine (High-Dose Fluzone \[HD vaccine\]), or 2) the standard dose (SD) trivalent influenza vaccine (Fluzone \[SD vaccine\]) for their residents. Additionally, half the facilities will receive free SD vaccine for their staff and the remaining facilities will practice usual care (no free vaccine) for staff. BACKGROUND: Influenza and pneumonia (P&I) are leading infectious causes of hospitalization and mortality in community-dwelling older adults and residents of long-term custodial care facilities or nursing homes (NH), and produce substantial annual health care costs. The elderly incur over 90% of this disease burden and NH residents are especially vulnerable given immune senescence, multimorbidity, and close living quarters. While hospitalization rates for NH residents vary considerably between facilities, most occur during the sixteen weeks of peak influenza activity annually. Influenza vaccination, a mainstay in prevention, is recommended in the U.S. for all individuals six months of age and older. Vaccination associates with reduced rates of stroke, heart attack, hospitalization, and death in non-institutional older adult populations. However, the benefit of influenza vaccine for the elderly in general has been questioned, a salient concern for frail elderly, such as NH residents. Influenza vaccination rates vary substantially between nursing homes. Influenza vaccine response declines with advancing age, indicating the need for a better vaccine. OBJECTIVES: The primary objective is to estimate the differences in all-cause hospitalization rates during influenza season experienced by long-stay nursing home residents, between facilities using HD vaccine vs. SD vaccine. The secondary objective is to estimate the differences in the likelihood of Activities of Daily Living (ADL) functional decline and mortality rates in the study nursing homes.

Interventions

BIOLOGICALHD Vaccine

Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.

BIOLOGICALSD Vaccine

Nursing home residents are allocated to receive standard-dose vaccine.

BIOLOGICALFree Vaccine

Nursing home facilities are provided free standard-dose vaccine for their staff.

BIOLOGICALUsual Care

Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.

Sponsors

Brown University
CollaboratorOTHER
Case Western Reserve University
CollaboratorOTHER
Insight Therapeutics, LLC
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Long-term care facilities within 50 miles of one of the 122 cities that serve as CDC surveillance sites

Exclusion criteria

* Facilities already systematically administering HD vaccine to their residents * Facilities having fewer than 50 long-stay residents * Hospital-based facilities * Facilities with more than 20% of the population under age 65 * Facilities not submitting Minimum Data Set (MDS) data

Design outcomes

Primary

MeasureTime frame
Hospitalization rateup to 1 year

Secondary

MeasureTime frame
Change in activities of daily living (ADL) scoresup to 1 year
Facility-level mortality rateup to 1 year
Cost difference between vaccine typesup to 3 years
Effect of facility policies on staff vaccination ratesup to 3 years
Hospitalization rate based on vaccine type and influenza strainUp to 3 years

Other

MeasureTime frameDescription
Difference in hospitalization claims based on staff vaccination statusup to 1 yearEffect on clinical outcomes of nursing home residents based on staff vaccine uptake.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026